EE05134B1 - Adamantaani derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine ravis - Google Patents
Adamantaani derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine ravisInfo
- Publication number
- EE05134B1 EE05134B1 EEP200200330A EEP200200330A EE05134B1 EE 05134 B1 EE05134 B1 EE 05134B1 EE P200200330 A EEP200200330 A EE P200200330A EE P200200330 A EEP200200330 A EE P200200330A EE 05134 B1 EE05134 B1 EE 05134B1
- Authority
- EE
- Estonia
- Prior art keywords
- therapy
- preparation
- pharmaceutical compositions
- compositions containing
- adamantane derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904651A SE9904651D0 (sv) | 1999-12-17 | 1999-12-17 | Novel compounds |
GB0015744A GB0015744D0 (en) | 2000-06-27 | 2000-06-27 | Novel compounds |
GB0017942A GB0017942D0 (en) | 2000-07-22 | 2000-07-22 | Novel compounds |
PCT/SE2000/002505 WO2001044170A1 (en) | 1999-12-17 | 2000-12-12 | Adamantane derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200330A EE200200330A (et) | 2003-10-15 |
EE05134B1 true EE05134B1 (et) | 2009-02-16 |
Family
ID=27255782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200330A EE05134B1 (et) | 1999-12-17 | 2000-12-12 | Adamantaani derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine ravis |
Country Status (32)
Country | Link |
---|---|
US (5) | US6881754B2 (sk) |
EP (5) | EP1352896B1 (sk) |
JP (2) | JP3710418B2 (sk) |
KR (2) | KR100710110B1 (sk) |
CN (1) | CN1312120C (sk) |
AR (1) | AR035325A1 (sk) |
AT (4) | ATE358117T1 (sk) |
AU (2) | AU780506B2 (sk) |
BR (1) | BRPI0016395B8 (sk) |
CA (1) | CA2393352C (sk) |
CO (1) | CO5251381A1 (sk) |
CY (3) | CY1106357T1 (sk) |
CZ (1) | CZ20022093A3 (sk) |
DE (4) | DE60036968T2 (sk) |
DK (4) | DK1352895T3 (sk) |
EE (1) | EE05134B1 (sk) |
ES (4) | ES2282546T3 (sk) |
HK (2) | HK1057035A1 (sk) |
HU (1) | HUP0300616A3 (sk) |
IL (2) | IL150124A0 (sk) |
IS (1) | IS2246B (sk) |
MX (1) | MXPA02005789A (sk) |
MY (1) | MY125978A (sk) |
NO (1) | NO328682B1 (sk) |
NZ (1) | NZ519378A (sk) |
PL (1) | PL200836B1 (sk) |
PT (4) | PT1352897E (sk) |
SI (1) | SI1352895T1 (sk) |
SK (1) | SK286987B6 (sk) |
TR (1) | TR200401432T4 (sk) |
TW (1) | TWI258462B (sk) |
WO (1) | WO2001044170A1 (sk) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
JP4731468B2 (ja) * | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | P2x7受容体のベンズアミド阻害剤 |
US20070010497A1 (en) * | 2003-05-29 | 2007-01-11 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
EP1633401A1 (en) * | 2003-05-29 | 2006-03-15 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
WO2004105796A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
EP1763353A1 (en) * | 2004-06-29 | 2007-03-21 | Warner-Lambert Company LLC | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR |
AU2005258911A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
US20060063834A1 (en) * | 2004-09-09 | 2006-03-23 | Frangioni John V | Substituted adamantanes, and methods of making the same |
SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
EP1906960A4 (en) * | 2005-07-11 | 2010-03-10 | Astrazeneca Ab | NEW COMBINATION 1 |
TW200819416A (en) * | 2006-09-05 | 2008-05-01 | Astrazeneca Ab | Novel process 470 |
BRPI0908353B8 (pt) | 2008-02-06 | 2021-05-25 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica |
NZ587799A (en) | 2008-03-25 | 2012-06-29 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CN102395562A (zh) | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
GB2469915A (en) * | 2009-04-30 | 2010-11-03 | Astrazeneca Ab | 2-chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec- 1-ylmethyl)-benzamide hydrochloride salt |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
JP2013249256A (ja) * | 2010-09-15 | 2013-12-12 | Astellas Pharma Inc | 脂肪性肝疾患治療薬 |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
BR112014001454A2 (pt) | 2011-07-22 | 2017-06-27 | Actelion Pharmaceuticals Ltd | derivados de amidas heterocíclicas como antagonistas do receptor de p2x7 |
JP6111268B2 (ja) | 2012-01-20 | 2017-04-05 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | P2x7受容体アンタゴニストとしての複素環アミド誘導体 |
EP2931717B1 (en) | 2012-12-12 | 2016-12-07 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
EP2956135B1 (en) | 2013-01-22 | 2016-11-16 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2956457B1 (en) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
WO2023158601A2 (en) * | 2022-02-15 | 2023-08-24 | The Children's Medical Center Corporation | Compositions and methods relating to atp/p2x7r signaling inhibition |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3029241A (en) * | 1962-04-10 | Phenylpbperazinylacyl anilines | ||
US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
US3732305A (en) * | 1970-03-03 | 1973-05-08 | Us Army | S-substituted thiosulfuric acid derivatives and preparation thereof |
US3789072A (en) * | 1970-04-22 | 1974-01-29 | Squibb & Sons Inc | Carboxamides |
FR2346011A1 (fr) | 1976-02-02 | 1977-10-28 | Orsymonde | Acetanilido-piperazines |
ZA825719B (en) | 1981-09-03 | 1983-06-29 | Recordati Chem Pharm | Alkanoylanilides |
CA2015473C (en) | 1989-04-28 | 1998-04-14 | Iwao Kinoshita | Triphenylmethane derivatives |
US6021024A (en) * | 1992-02-21 | 2000-02-01 | Kabushiki Kaisha Toshiba | Magnetic disk drive having a constant skew angle |
CA2091194A1 (en) | 1992-04-08 | 1993-10-09 | Richard D. Connell | 2-oxo-ethyl derivatives as immunosuppressants |
EP0582164B1 (en) | 1992-07-31 | 1998-12-23 | Bristol-Myers Squibb Company | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles |
ATE197146T1 (de) | 1993-08-10 | 2000-11-15 | Black James Foundation | Gastrin-und cck-rezeptorligande |
US5530018A (en) * | 1994-02-04 | 1996-06-25 | G. D. Searle & Co. | Meso-azanoradamantanes |
GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
US5912260A (en) | 1994-05-27 | 1999-06-15 | James Black Foundation Limited | Gastrin and CCK antagonists |
AU701127B2 (en) | 1994-10-27 | 1999-01-21 | Merck & Co., Inc. | Muscarine antagonists |
DE19608653A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
AU1903799A (en) * | 1997-12-05 | 1999-06-28 | Eisai Co. Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
US6018089A (en) * | 1997-12-09 | 2000-01-25 | Shell Oil Company | Process for separating linear internal olefins from branched internal olefins |
WO1999031096A1 (en) | 1997-12-18 | 1999-06-24 | Shaman Pharmaceuticals, Inc. | Piperazine derivatives useful as hypoglycemic agents |
AU3985699A (en) | 1998-05-19 | 1999-12-06 | Centaur Pharmaceuticals, Inc. | Amide therapeutics for the treatment of inflammatory bowel disease |
BR0009651A (pt) | 1999-04-09 | 2002-01-08 | Astrazeneca Ab | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas |
SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
US6555451B1 (en) * | 2001-09-28 | 2003-04-29 | The United States Of America As Represented By The Secretary Of The Navy | Method for making shallow diffusion junctions in semiconductors using elemental doping |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
SE0302488D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
-
2000
- 2000-12-04 TW TW089125761A patent/TWI258462B/zh not_active IP Right Cessation
- 2000-12-12 JP JP2001545259A patent/JP3710418B2/ja not_active Expired - Lifetime
- 2000-12-12 DK DK03013989T patent/DK1352895T3/da active
- 2000-12-12 IL IL15012400A patent/IL150124A0/xx not_active IP Right Cessation
- 2000-12-12 AT AT03013989T patent/ATE358117T1/de active
- 2000-12-12 PT PT03013991T patent/PT1352897E/pt unknown
- 2000-12-12 DE DE60036968T patent/DE60036968T2/de not_active Expired - Lifetime
- 2000-12-12 EP EP03013990A patent/EP1352896B1/en not_active Expired - Lifetime
- 2000-12-12 PT PT03013990T patent/PT1352896E/pt unknown
- 2000-12-12 KR KR1020027007702A patent/KR100710110B1/ko active IP Right Grant
- 2000-12-12 EP EP03013989A patent/EP1352895B1/en not_active Expired - Lifetime
- 2000-12-12 US US10/149,549 patent/US6881754B2/en not_active Expired - Lifetime
- 2000-12-12 AT AT03013991T patent/ATE350364T1/de active
- 2000-12-12 WO PCT/SE2000/002505 patent/WO2001044170A1/en active Application Filing
- 2000-12-12 DE DE60034155T patent/DE60034155T2/de not_active Expired - Lifetime
- 2000-12-12 DE DE60032823T patent/DE60032823T2/de not_active Expired - Lifetime
- 2000-12-12 DK DK03013991T patent/DK1352897T3/da active
- 2000-12-12 SI SI200030950T patent/SI1352895T1/sl unknown
- 2000-12-12 PT PT00986155T patent/PT1242364E/pt unknown
- 2000-12-12 EE EEP200200330A patent/EE05134B1/xx not_active IP Right Cessation
- 2000-12-12 EP EP07014968A patent/EP1862451A1/en not_active Withdrawn
- 2000-12-12 SK SK841-2002A patent/SK286987B6/sk not_active IP Right Cessation
- 2000-12-12 AU AU22444/01A patent/AU780506B2/en not_active Expired
- 2000-12-12 PL PL355913A patent/PL200836B1/pl not_active IP Right Cessation
- 2000-12-12 AT AT00986155T patent/ATE261933T1/de active
- 2000-12-12 ES ES03013989T patent/ES2282546T3/es not_active Expired - Lifetime
- 2000-12-12 AT AT03013990T patent/ATE376994T1/de active
- 2000-12-12 CO CO00094336A patent/CO5251381A1/es not_active Application Discontinuation
- 2000-12-12 EP EP00986155A patent/EP1242364B1/en not_active Expired - Lifetime
- 2000-12-12 HU HU0300616A patent/HUP0300616A3/hu unknown
- 2000-12-12 ES ES00986155T patent/ES2215777T3/es not_active Expired - Lifetime
- 2000-12-12 DE DE60009147T patent/DE60009147T2/de not_active Expired - Lifetime
- 2000-12-12 KR KR1020077000596A patent/KR20070012883A/ko not_active Application Discontinuation
- 2000-12-12 PT PT03013989T patent/PT1352895E/pt unknown
- 2000-12-12 MX MXPA02005789A patent/MXPA02005789A/es active IP Right Grant
- 2000-12-12 ES ES03013991T patent/ES2279031T3/es not_active Expired - Lifetime
- 2000-12-12 DK DK00986155T patent/DK1242364T3/da active
- 2000-12-12 CN CNB008189226A patent/CN1312120C/zh not_active Expired - Lifetime
- 2000-12-12 TR TR2004/01432T patent/TR200401432T4/xx unknown
- 2000-12-12 CZ CZ20022093A patent/CZ20022093A3/cs unknown
- 2000-12-12 DK DK03013990T patent/DK1352896T3/da active
- 2000-12-12 EP EP03013991A patent/EP1352897B1/en not_active Expired - Lifetime
- 2000-12-12 CA CA2393352A patent/CA2393352C/en not_active Expired - Lifetime
- 2000-12-12 ES ES03013990T patent/ES2294219T3/es not_active Expired - Lifetime
- 2000-12-12 BR BRPI0016395A patent/BRPI0016395B8/pt not_active IP Right Cessation
- 2000-12-12 NZ NZ519378A patent/NZ519378A/en not_active IP Right Cessation
- 2000-12-15 AR ARP000106695A patent/AR035325A1/es active IP Right Grant
- 2000-12-15 MY MYPI20005926A patent/MY125978A/en unknown
-
2002
- 2002-05-31 IS IS6406A patent/IS2246B/is unknown
- 2002-06-14 NO NO20022856A patent/NO328682B1/no not_active IP Right Cessation
- 2002-11-11 HK HK03109398A patent/HK1057035A1/xx not_active IP Right Cessation
- 2002-11-11 HK HK02108164.1A patent/HK1046678B/zh not_active IP Right Cessation
-
2004
- 2004-03-31 US US10/813,426 patent/US7132457B2/en not_active Expired - Lifetime
-
2005
- 2005-05-27 AU AU2005202321A patent/AU2005202321B2/en not_active Ceased
- 2005-06-03 JP JP2005163710A patent/JP2005320340A/ja active Pending
-
2006
- 2006-09-29 US US11/529,746 patent/US7297818B2/en not_active Expired - Fee Related
-
2007
- 2007-03-06 CY CY20071100312T patent/CY1106357T1/el unknown
- 2007-05-17 CY CY20071100671T patent/CY1106602T1/el unknown
- 2007-06-20 US US11/812,673 patent/US20080139636A1/en not_active Abandoned
- 2007-12-19 CY CY20071101609T patent/CY1107838T1/el unknown
-
2008
- 2008-02-25 IL IL189758A patent/IL189758A0/en not_active IP Right Cessation
- 2008-12-04 US US12/314,156 patent/US20090176853A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05134B1 (et) | Adamantaani derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
EE200100431A (et) | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine | |
EE04399B1 (et) | Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
EE04463B1 (et) | 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis | |
EE200100684A (et) | Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
EE200100446A (et) | Uued tritsüklilised ühendid ja nende kasutamine meditsiinis: nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
HUP0203548A3 (en) | New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0300618A3 (en) | Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
EE05149B1 (et) | Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis | |
EE05181B1 (et) | Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks | |
EE04565B1 (et) | Adamantaani derivaadid, nende saamine ja kasutamine | |
HUP0303529A3 (en) | New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP0204515A3 (en) | 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
EE200200065A (et) | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon | |
IL153167A0 (en) | Phenyl derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy | |
HUP0204245A3 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
EE04679B1 (et) | Tuumorivastase toimega kamptotetsiini derivaadid,meetod nende valmistamiseks ja neid hendeid sisaldavad farmatseutilised kompositsioonid | |
EE200100037A (et) | Bensotsüklohepteenid, nende valmistamise meetod, neid sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks | |
EE200000037A (et) | Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena | |
EE200100470A (et) | Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine | |
EE04997B1 (et) | Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine | |
HUP0202075A3 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
EE9900112A (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
DE60037816D1 (de) | Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka | |
EE04311B1 (et) | Asoolid, nende valmistamismeetod, kasutamine ravimina ja farmatseutiline kompositsioon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20111212 |